Abnormal visual experiences in individuals with histories of hallucinogen use: A web-based questionnaire
This questionnaire-based study (n=2455) found that the risk of Hallucinogen Persisting Perception Disorder (HPPD) may increase with greater past exposure to specific hallucinogens, symptoms were rarely (4.2%) perceived as distressing/impairing.
Authors
- Earth Erowid
- Fire Erowid
Published
Abstract
Despite longstanding reports of prolonged or reoccurring perceptual changes in a subset of hallucinogen users, very little is known about Hallucinogen Persisting Perception Disorder and related visual abnormalities in hallucinogen users. We used an online questionnaire to document the symptoms and relationship to drug use of unusual visual phenomena in hallucinogen users. 16,192 individuals viewed the information sheet and 2679 were included in the study. Of these, 224 reported having unrelated diagnoses associated with unusual visual experiences and were excluded from main analyses. Most (60.6%) of the remaining 2455 participants reported having experienced drug-free visual experiences that resembled hallucinogen effects. Probability of experiencing constant or near-constant symptoms was predicted by greater past exposure to specific hallucinogens, including lysergic acid diethylamide (LSD). Although symptoms were common, few (104, or 4.2% of the sample) found them distressing or impairing enough to consider seeking treatment. Visual changes in hallucinogen users may be more common than previously suspected and are worthy of further study.
Research Summary of 'Abnormal visual experiences in individuals with histories of hallucinogen use: A web-based questionnaire'
Introduction
Hallucinogen use is common, especially among young adults, and a minority of users report prolonged or recurring perceptual changes. The DSM-IV-TR recognises a syndrome termed Hallucinogen Persisting Perception Disorder (HPPD), but the literature on its prevalence, phenomenology, and risk factors is limited and sometimes conflicting. Prior reports emphasise visual disturbances—geometric imagery, motion-perception abnormalities, halos, afterimages, and colour flashes—but many studies are case series or small samples, and some apparent cases may overlap with other conditions such as psychosis, migraine aura, seizures, or stroke. Whether persisting visual changes represent a rare complication of specific drugs (notably LSD) or a more widespread, drug-triggered vulnerability remains uncertain. Baggott and colleagues therefore conducted an exploratory web-based questionnaire study to document the frequency and characteristics of drug-free visual phenomena among people with histories of hallucinogen use, and to examine relationships between these experiences and past exposure to specific psychoactive substances. The investigators chose an online approach to access a large, difficult-to-reach population and to gather initial descriptive data that might guide more objective follow-up research.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Baggott, M., Coyle, J., Erowid, E., Erowid, F., & Robertson, L. (2011). Abnormal visual experiences in individuals with histories of hallucinogen use: A web-based questionnaire. Drug and Alcohol Dependence, 114(1), 61-67. https://doi.org/10.1016/j.drugalcdep.2010.09.006
References (2)
Papers cited by this study that are also in Blossom
Halpern, J. H., Pope Jr, H. G. · Drug and Alcohol Dependence (2003)
Gelkopf, M., Skladman, I., Rudinski, D. et al. · International Clinical Psychopharmacology (2003)
Cited By (23)
Papers in Blossom that reference this study
Meikle, S., Carter, O., Liknaitzky, P. et al. · Therapeutic Advances in Psychopharmacology (2025)
Zhou, K., De Wied, D., Carhart-Harris, R. L. et al. · PNAS (2025)
Hinkle, J. T., Graziosi, M., Nayak, S. et al. · JAMA Psychiatry (2024)
McGovern, H., Grimmer, H. J., Doss, M. K. et al. · Communications Psychology (2024)
Evans, J., Robinson, O., Ketzitzidou-Argyri, E. et al. · PLOS ONE (2023)
Simonsson, O., Goldberg, S. B., Chambers, R. et al. · Psychopharmacology (2023)
Ortiz Bernal, A. M., Raison, C. L., Lancelotta, R. et al. · Frontiers in Psychiatry (2022)
Van Der Walt, A., Ford, H., Fraser, C. L. et al. · Frontiers in Neurology (2022)
Doyle, M. A., Ling, S., Lui, L. M. W. et al. · Expert Opinion on Drug Safety (2022)
Kopra, E., Ferris, J. A., Winstock, A. R. et al. · Journal of Psychopharmacology (2022)
Show all 23 papersShow fewer
Richards, W. A., Garcia-Romeu, A. · International Review of Psychiatry (2018)
Jungaberle, H., Thal, S., Zeuch, A. et al. · Neuropharmacology (2018)
Martinotti, G., Santacroce, R., Pettorruso, M. et al. · Brain Sciences (2018)
Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R. et al. · Trends in Pharmacological Sciences (2017)
Liechti, M. E. · Neuropsychopharmacology (2017)
Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)
Garcia-Romeu, A., Kersgaard, B., Addy, P. H. · Experimental and Clinical Psychopharmacology (2016)
McKenna, D., Riba, J. · Current Topics in Behavioral Neurosciences (2016)
Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Litjens, R. P. W., Brunt, T. M., Alderliefste, G. et al. · European Neuropsychopharmacology (2014)
MacLean, K. A., Leoutsakos, J. S., Johnson, M. W. et al. · Journal for the Scientific Study of Religion (2012)
Maclean, K. A., Johnson, M. W., Reissig, C. J. et al. · Psychopharmacology (2012)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.